Jevtana (Cabazitaxel)

Cabazitaxel binds to tubulin subunits, promoting polymerization and stabilizing microtubules. This prevents the normal dynamic reorganization required for mitosis, leading to cell‑cycle arrest at the G2/M phase and ultimately triggering apoptosis of rapidly dividing cancer cells. Its activity is independent of common taxane resistance mechanisms.

The specific dose and infusion schedule of Jevtana are determined by the treating oncologist based on the patient’s clinical status, body surface area, and prior therapy. The prescribing information provides detailed guidance, and the prescriber tailors the regimen to achieve optimal efficacy while managing safety.

Cabazitaxel is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided in pregnant women unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug may be excreted in milk and could harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assistance with import documentation.

Both cabazitaxel and docetaxel belong to the taxane class and disrupt microtubule dynamics, but cabazitaxel has been designed to retain activity in tumors that have become resistant to docetaxel. Clinical studies show cabazitaxel can improve overall survival in patients who have progressed after docetaxel, though its safety profile includes a higher incidence of neutropenia.

Jevtana is supplied as a sterile injectable solution in 20 mg vials. It must be stored refrigerated at 2–8 °C, protected from light, and should not be frozen or shaken. Prior to infusion, the vial may be allowed to reach room temperature, but the solution must be used within the time frame specified in the label after reconstitution.

Jevtana is given by intravenous infusion, typically over a period of one hour, on a schedule determined by the oncologist (often every three weeks). The infusion is performed in a clinical setting where vital signs and blood counts can be monitored before, during, and after administration to manage potential adverse reactions.

The most serious risks include severe neutropenia that can lead to infection, febrile neutropenia, hypersensitivity reactions, and rare but potentially fatal events such as pulmonary embolism or severe hepatic toxicity. Patients should be closely monitored for signs of infection, bleeding, liver dysfunction, and allergic responses throughout treatment.

Jevtana is contraindicated in patients with known hypersensitivity to cabazitaxel or any component of the formulation. It should also be avoided in individuals with uncontrolled infections, severe hepatic impairment, or those who are pregnant unless the therapeutic benefit outweighs the risk. Clinicians must assess each patient’s medical history before initiating therapy.